Mr. Shawn Guse is a co-founder and the President and CEO of Intuitive Biosciences. Mr. Guse previously served as Vice President and General Counsel at TomoTherapy where he led the largest initial public offering in Wisconsin history and also led its licensing and acquisition activities. Mr. Guse started his career in Law serving in private practice for more than 10 years. Mr. Guse received his law degree from the University of Wisconsin in 1995.
Dr. William Patterson became Director of R&D for Intuitive Biosciences at the company’s inception in March, 2012, and held the same role at Isthmus Biosciences, a basic research arm of Intuitive Biosciences, until 2015. Prior to Intuitive Biosciences, Bill played a role as Director of R&D at Gentel Biosciences from 2010 to 2012, and served in many other R&D roles for companies such as Primorigen Biosciences (2006-2009), Pierce Biotech (2004-2006) and Promega (1992-2004). Bill has extensive experience working in protein expression, purification, protein analysis, and antibody microarray technology. Bill received his PhD in Biochemistry from the University of Illinois at Urbana-Champaign in 1993.
Dr. John Bart joined Intuitive Biosciences in March 2012 and currently serves as Director of Manufacturing. Prior to joining Intuitive, John worked for Gentel Biosciences with roles as Senior Scientist and later as Manufacturing Manager. Previously John worked for eight years at ThermoElectron as a Senior Scientist. John has nearly two decades of industrial and government experience doing product development, production and QA/QC in the areas of protein microarray, Medical Diagnostics and immunosensors. John received his PhD in Chemistry from Caltech in 1994.
Dr. Kimberly Luke joined Intuitive Biosciences in March 2012 and currently serves as Director of Commercial Development. Prior to Intuitive Biosciences, Kim served in various scientific roles for Gentel Biosciences, each with increasing level of responsibility. Kim has extensive experience in microarray assay development and production and has worked at both Pharmacia and Affymetrix. Kim received her PhD in 2006 from the University of Wisconsin-Madison with a focus in microbiology.